Advancements in medical imaging have brought FDG PET/MRI to the forefront, particularly in cancer diagnostics. A review in the American Journal of Roentgenology sheds light on the comparative efficacy of FDG PET/MRI and FDG PET/CT, demonstrating that the former often provides superior diagnostic performance.
The integration of FDG PET with MRI has seen substantial growth, promising enhanced diagnostic capabilities for oncologists. This study reviews existing evidence, comparing the diagnostic performance of FDG PET/MRI and FDG PET/CT in cancer patients.
Researchers conducted an extensive search across MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews, covering studies from July 1, 2015, to January 25, 2023. The review focused on studies presenting head-to-head comparisons of FDG PET/CT and FDG PET/MRI in cancer diagnostics. The meta-analysis utilized bivariate modeling to generate pooled sensitivity and specificity estimates for both imaging modalities.
The review incorporated data from 29 studies, encompassing 1,656 patients. Significant findings include:
- Patient-level Detection of Regional Nodal Metastases:
- PET/MRI: Sensitivity 88% (95% CI, 74-95%), Specificity 92% (95% CI, 71-98%)
- PET/CT: Sensitivity 86% (95% CI, 70-94%), Specificity 86% (95% CI, 68-95%)
- Lesion-level Detection of Recurrence and/or Metastases:
- PET/MRI: Sensitivity 94% (95% CI, 78-99%), Specificity 83% (95% CI, 76-88%)
- PET/CT: Sensitivity 91% (95% CI, 77-96%), Specificity 81% (95% CI, 72-88%)
Individual studies not included in the meta-analysis also highlighted the superiority of PET/MRI:
- Breast Cancer Staging Accuracy: 98.0% (PET/MRI) vs. 74.5% (PET/CT)
- Colorectal Cancer Staging Accuracy: 96.2% (PET/MRI) vs. 69.2% (PET/CT)
- Primary Tumor Detection in Cervical Cancer: Sensitivity 93.2% (PET/MRI) vs. 66.2% (PET/CT)
- Lesion-level Liver Metastasis Detection:
- Sensitivity: 91.1-98.0% (PET/MRI) vs. 42.3-71.1% (PET/CT)
- Specificity: 100.0% (PET/MRI) vs. 83.3-98.6% (PET/CT)
- Accuracy: 96.5-98.2% (PET/MRI) vs. 44.7-86.7% (PET/CT)
PET/MRI had a more significant impact on patient management decisions in three studies, influencing management in 5.2-11.1% of cases compared to 0.0-2.6% with PET/CT. The findings underscore PET/MRI’s comparable or superior diagnostic performance relative to PET/CT across various cancers and diagnostic endpoints.